tradingkey.logo

Trevi Therapeutics Announces Positive Topline Results From Phase 2B Coral Trial Of Haduvio

ReutersJun 2, 2025 12:20 PM

- Trevi Therapeutics Inc TRVI.O:

  • TREVI THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE PHASE 2B CORAL TRIAL OF HADUVIO IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS CHRONIC COUGH

  • TREVI THERAPEUTICS INC - TO REQUEST END-OF-PHASE 2 MEETING WITH FDA, PHASE 3 IN 2026

  • TREVI THERAPEUTICS INC - HADUVIO MET PRIMARY ENDPOINT , ACHIEVES -43.3% PLACEBO-ADJUSTED CHANGE IN COUGH FREQUENCY AT 108 MG BID

  • TREVI THERAPEUTICS INC - HADUVIO WELL-TOLERATED WITH SIMILAR DISCONTINUATION RATES TO PLACEBO

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI